Plasmatech Biopharmaceuticals Inc Stock Nasdaq
Stocks
US72754H1095
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 08-05 | Abeona Therapeutics Inc. Grants New Technology Add-On Payment Status For ZEVASKYN | CI |
| 06-29 | Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell 3000E Growth Benchmark | CI |
| Market Cap | 393M 340M 318M 291M 548M 37.43B 557M 3.73B 1.46B 18.76B 1.48B 1.44B 62.02B | P/E 2026 * |
-9.34x | P/E 2027 * | -98.6x |
|---|---|---|---|---|---|
| Enterprise Value | 393M 340M 318M 291M 548M 37.43B 557M 3.73B 1.46B 18.76B 1.48B 1.44B 62.02B | EV / Sales 2026 * |
6x | EV / Sales 2027 * | 2.91x |
| Free-Float |
79.49% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Plasmatech Biopharmaceuticals Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Vishwas Seshadri
CEO | Chief Executive Officer | 50 | 15/10/2021 |
Joseph Vazzano
DFI | Director of Finance/CFO | 42 | 14/03/2022 |
James A. Gow
CTO | Chief Tech/Sci/R&D Officer | - | 20/10/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Alvino
BRD | Director/Board Member | 58 | 01/03/2006 |
Faith Charles
BRD | Director/Board Member | 64 | 25/03/2021 |
Leila Alland
BRD | Director/Board Member | 63 | 19/04/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.26% | +2.39% | +39.48% | +0.78% | 77.1B | |
| -0.84% | +0.09% | +20.92% | +179.15% | 49.43B | |
| +2.77% | +1.90% | -1.84% | +27.14% | 49.27B | |
| -0.13% | +3.33% | -50.97% | -50.14% | 44.59B | |
| +0.13% | +1.67% | +61.51% | -23.93% | 30.48B | |
| +1.71% | +0.60% | +53.76% | +85.24% | 24B | |
| +7.01% | +5.24% | +116.80% | -42.99% | 21.5B | |
| +4.29% | +7.66% | -3.26% | +189.18% | 20.18B | |
| +1.66% | -3.70% | +65.40% | +123.91% | 16.29B | |
| Average | +1.98% | +0.79% | +33.53% | +54.26% | 36.98B | |
| Weighted average by Cap. | +1.49% | +2.58% | +25.21% | +42.80% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 65.51M 56.67M 52.92M 48.54M 91.3M 6.23B 92.75M 621M 244M 3.12B 246M 241M 10.33B | 135M 117M 109M 100M 188M 12.84B 191M 1.28B 502M 6.44B 507M 496M 21.28B |
| Net income | -42.25M -36.55M -34.13M -31.31M -58.89M -4.02B -59.83M -400M -157M -2.02B -159M -155M -6.66B | -2.1M -1.82M -1.7M -1.56M -2.93M -200M -2.98M -19.91M -7.82M -100M -7.89M -7.72M -331M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
